1 / 44

HER2 pos. Disease Supportive care

HER2 pos. Disease Supportive care. Hans Wildiers University Hospitals Leuven. HER2 pos. Disease Adjuvant T rastuzumab : HERA (2y vs 1y) Phare (6 mo vs 1y ) NSABP B-31 and NCCTG N9831 (1y vs nil) Metastatic Pertuzumab : Cleopatra HER2 Translational Supportive care

tracy
Télécharger la présentation

HER2 pos. Disease Supportive care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HER2 pos. Disease Supportive care Hans Wildiers University Hospitals Leuven

  2. HER2 pos. Disease • Adjuvant Trastuzumab: • HERA (2y vs 1y) • Phare (6 movs 1y) • NSABP B-31 and NCCTG N9831 (1y vs nil) • Metastatic Pertuzumab: Cleopatra • HER2 Translational • Supportive care • MDS/AML after breast cancer • Neurocognitive impact of adjuvant chemotherapy • Bone

  3. HER2 adjuvant S5-2 HERA TRIAL UPDATE at 8 y FUP Accrual 2001 – 2005 (n=5102) Women with locally determined HER2-positive invasive early breast cancer Surgery + (neo)adjuvant CT ± RT Centrally confirmed IHC 3+ or FISH+ and LVEF ≥ 55% Randomization OBSERVATION n=1698 1 year Trastuzumab 8 mg/kg – 6 mg/kg 3 weekly schedule n=1703 2 years Trastuzumab 8 mg/kg – 6 mg/kg 3 weekly schedule n=1701 After ASCO 2005, option of switch to Trastuzumab Final analysis planned for 725 disease-free survival (DFS) events to obtain 80% power to detect a true hazard ratio of 0.80. CT, chemotherapy; RT, radiotherapy

  4. HER2 adjuvant S5-2 DFS FOR 2 YEARS VS. 1 YEAR TRASTUZUMAB AT 8 YRS MFU 100 89.1% 81.6% 75.8% 86.7% 80 81.0% 76.0% 60 Trastuzumab 2 years Disease-free survival (%) Trastuzumab 1 year 40 20 0 0 1 2 3 4 5 6 7 8 9 Years from randomization

  5. HER2 adjuvant S5-2 DFS BY HORMONE RECEPTOR STATUS AT 8 YRS MFU Hormone receptor positive 92.6% received endocrine therapy Hormone receptor negative 2.8% received endocrine therapy 100 100 90.3% 87.8% 83.1% 80.1% 76.1% 75.4% 89.6% 80 80 82.9% 83.8% 78.9% 77.2% 74.7% 60 60 Disease-free survival (%) Disease-free survival (%) 40 40 Trastuzumab 2 years Trastuzumab 2 years Trastuzumab 1 year Trastuzumab 1 year 20 20 0 0 0 0 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 Years from randomization Years from randomization

  6. HER2 adjuvant S5-2 OS FOR 2 YEARS VS. 1 YEAR TRASTUZUMAB AT 8 YRS MFU 97.4% 100 92.6% 86.4% 96.5% 91.4% 80 87.6% 60 Trastuzumab 2 years Overall Survival (%) Trastuzumab 1 year 40 20 0 0 1 2 3 4 5 6 7 8 9 Years from randomization

  7. HER2 adjuvant S5-2 ADVERSE EVENTS(SAFETY ANALYSIS POPULATION) 1 LVEF < 50% and ≥ 10% below baseline confirmed by repeat assessment, excluding patients with a primary cardiac endpoint. 2NYHA class III or IV, confirmed by a cardiologist, and LVEF < 50% and ≥ 10% below baseline, OR cardiac death.

  8. HER2 adjuvant S5-2 1 YEAR TRASTUZUMAB VS. OBSERVATION: DFS ITT ANALYSES DFS benefit Median follow-up (% follow-up timeafter selective crossover) No. of DFS events 1 year trastuzumab vs observation 0.54 2005 (0%) 127 vs 220 P<0.0001 1 yr MFU 0.64 2006 (4.3%) 218 vs 321 P<0.0001 2 yrs MFU 0.76 2008 (33.8%) 369 vs 458 P<0.0001 4 yrs MFU 0.76 2012 (48.6%) 471 vs 570 P<0.0001 8 yrs MFU Favours 1 year trastuzumab Favours observation 0 1 2 HR (95% CI) Extended from Gianni et al. Lancet Oncol. 2011.

  9. HER2 adjuvant S5-2 1 YEAR TRASTUZUMAB VS. OBSERVATION:OSITT ANALYSES OS benefit Median follow-up (% follow-up timeafter selective crossover) No. of deaths 1 year trastuzumab vsobservation 0.76 2005 (0%) 29 vs 37 P=0.26 1 yr MFU 0.66 2006 (4.1%) 59 vs 90 P=0.0115 2 yrs MFU 0.85 2008 (30.9%) 182 vs 213 P=0.1087 4 yrs MFU 0.76 2012 (45.5%) 278 vs 350 P=0.0005 8 yrs MFU Favours 1 year trastuzumab Favours observation 0 1 2 HR (95% CI) Extended from Gianni et al. Lancet Oncol. 2011.

  10. HER2 adjuvant PHARE*Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer S5-3 • Protocol of • Herceptin® • Adjuvant with • Reduced • Exposure Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin,Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Nicole Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat, Iris Pauporté, Andrew Kramar. • *lighthouse in French

  11. HER2 adjuvant S5-3 Study design trastuzumabup to 12 months trastuzumab 6 months R Stratification 1. ER pos / neg 2. Chemo: conco/ seq stop trastuzumab Clinical exam LVEF … 0 3 6 9 12 15 18 21 24 30 mos Mammography Up to 60 mos… R: Randomizationafterinformed consent

  12. HER2 adjuvant S5-3 Statistical Methods • Non inferiority randomized trial • 2% variation in terms of absolute difference of recurrence • The 95% CI HR margins should not cross the 1.15 boundary • 1040 DFS events required for 80% power at 5% level or 4 years of accrual and at least 2 years of follow-up • HR were estimated from the stratified Cox model • Accrual target: 3400 patients

  13. HER2 adjuvant S5-3 Treatment Characteristics

  14. HER2 adjuvant S5-3 DFS Events 42.5mos. median Follow-up

  15. HER2 adjuvant S5-3 Disease Free Survival 97.0 93.8 90.7 87.8 95.5 91.2 87.8 84.9 EventsHR95%CIp-value T 12m 176 T 6m 219 1.28 (1.05 – 1.56) 0.29 * Cox model stratified by ER status and concomitant chemotherapy

  16. HER2 adjuvant S5-3 Primary endpoint scenarios A Equivalent B Superior PHARE trial C D Non Inferior E Inferior .85 1 1.15 1.3 1.45 1.6 HR X Pivot et al, ESMO 2012, LBA5_PR

  17. HER2 adjuvant S5-3 Subanalysis

  18. HER2 adjuvant S5-5 Trastuzumab plus Adjuvant Chemotherapy for HER2-positive Breast Cancer: Final Planned Joint Analysis of Overall Survivalfrom NSABP B-31 and NCCTG N9831 Median follow-up: 8.4 years Definitive survival analysis at 710 OS events Abstract #S5-5 San Antonio Breast Cancer Symposium – December 4-8, 2012

  19. HER2 adjuvant San Antonio Breast Cancer Symposium, December 4-8, 2012 S5-5 N9831/B-31 Disease-Free Survival AC  P+H 81.4% 76.8% 73.7% A  P 64.9% 62.2% N Events AC→P 2018 680 AC→P+H 2028 473 HRadj=0.60 (95% CI: 0.53-0.68) P<0.0001

  20. HER2 adjuvant San Antonio Breast Cancer Symposium, December 4-8, 2012 S5-5 B-31/N9831 Overall Survival 89.8% 87.0% AC  P 90.3% 84.3% 79.4% ∆=2.9% ∆=5.5% ∆=7.6% ∆=8.8% N Events AC→P 2018 418 AC→P+H 2028 286

  21. HER2 metastatic P5-18-26 CLEOPATRA: update Placebo + trastuzumab PD n = 406 Docetaxel*≥ 6 cycles recommended Patients withHER2-positive MBCCentrally confirmed (N = 808) 1:1 Pertuzumab + trastuzumab PD n = 402 Docetaxel*≥ 6 cycles recommended • Primary endpoint: Independently-assessed progression-free survival (PFS) • Collection of tumor tissue (archival in >90%) and serum samples was mandatory • Study dosing q3w:− Pertuzumab/placebo: 840 mg loading dose, 420 mg maintenance− Trastuzumab: 8 mg/kg loading dose, 6 mg/kg maintenance− Docetaxel: 75 mg/m2, escalating to 100 mg/m2 if tolerated 1. Baselga J, et al. SABCS 2011 (Abstract S5-5);2. Baselga J, et al. N Engl J Med 2012; 366: 109–119. * < 6 cycles allowed for unacceptable toxicity or PD; > 6 cycles allowed at investigator discretionHER2, human epidermal growth factor receptor 2; PD, progressive disease

  22. HER2 metastatic P5-18-26 CLEOPATRA: overall survival 1 year 94% 100 2 years 90 89% 81% 3 years HR=0.6695% CI 0.52−0.84 p=0.0008 80 70 66% 69% 60 Overall survival (%) 50 50% 40 30 Ptz + T + D: 113 events; median not reached 20 Pla+ T + D: 154 events; median 37.6 months 10 0 0 5 10 15 20 25 30 35 40 45 50 55 Time (months) n at risk Ptz + T + D 402 387 371 342 317 230 143 84 33 9 0 0 Pla+ T + D 406 383 350 324 285 198 128 67 22 4 0 0 Stopping boundary for concluding statistical significance at this second interim analysis was p≤0.0138 D, docetaxel; Pla, placebo; Ptz, pertuzumab; T, trastuzumab

  23. HER2 metastatic P5-18-26 CLEOPATRA: PFS 100 Ptz + T + D: median 18.7 months ∆=6.3 months Pla+ T + D: median 12.4 months 90 80 70 60 Progression-free survival (%) HR=0.6995% CI 0.58−0.81 50 40 30 20 10 0 0 5 10 15 20 25 30 35 40 45 50 Time (months) n at risk Ptz + T + D 402 341 284 218 178 108 67 34 8 0 0 Pla+ T + D 406 329 223 148 110 72 42 26 8 0 0 D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab

  24. HER2 metastatic P5-18-01 CLEOPATRA PFS according to age 100 90 80 70 60 Progression-free survival (%) 50 40 30 20 10 0 0 5 10 15 20 25 30 35 Time (months) D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab

  25. HER2 metastatic P5-18-01 CLEOPATRA PFS according to age:Exposure to docetaxel treatment

  26. HER2 metastatic P5-18-01 CLEOPATRA PFS according to age:Ten most common grade ≥3 adverse events overall LVSD, left ventricular systolic dysfunction

  27. HER2 translational S5-7 The HER2 signalling pathway Selection of biomarkers HER ligands (AREG, EGF, TGFα) Y NO RESULTS (except HER2) sHER2 Y IGF1R EGFR HER2 HER3 HER2 ER Grb2 ER Ras Sos PI3K PTEN Sos Shc Grb2 Akt Raf mTOR GSK3 BAD FKHR MEK 1/2 p27 Cell survival MAPK Cyclin D1, E Cell-cycle progression Nucleus Cell proliferation c-myc

  28. HER2 translational • Neosphere: associatonbetweenpCR and immune biomarkersS6-7 • Lapatinibdecreases Ki67 by 27% in HER2 neg tumors in a ‘window of opportunity’ study(mainlyifalso high HER3 expression) PD07-07 • New techniquesforHER2 determination • Next generationsequencingis highly concordant with FISH for HER2, and uncoversactionablegenomicalterationsPD02-07 • MPLA PD02-03, • RNA scope analysis PD02-04 • AQUA: predictstrastuzumab benefit in BCIRG-005/6 PD02-01

  29. HER2 translational S5-6 ActivatingHER2 mutationsin HER2 Gene AmplificationNegativeBreastCancers • HER2 mutationspredominantlyoccur in HER2 gene amplificationnegativepatients. • The majority of HER2 mutations are activatingevents thatcauseoncogenictransformation, thusthey are highlylikelytobe driver events in these breastcancers. • Neratinibis a highly potent, irreversible pan-ErbBtyrosine kinase inhibitor forall of the HER2 mutations (clinical trial has been launched)

  30. AML/MDS S3-5 MDS/AML after BC diagnosis • Previousreports: • NSABP trials: 0,27% after AC at 8y  if RT afterlumpectomy or CSF use. • An “environmental” cancer

  31. AML/MDS S3-5

  32. AML/MDS S3-5 Characteristics of Leukemia cohort

  33. AML/MDS S3-5 Cumulativeincidence of Leukemia Chemo vs no chemo: HR 2,5 p0,007

  34. AML/MDS S3-5 Conclusions • Adjuvantchemotherapy was associatedwith a cumulative10-year incidence of leukemia of ~ 0.5% • Almost half of the events occurredbeyondyear 5 • Radiationaloneappearstobe a risk factor, but maynotaddmuchtopatientsalreadytreatedwithchemotherapy • Leukemia risk was notlimitedto MDS/AML, and cases of high risk lymphoidleukemiawereobserved • Thisstudyhighlights the challenges of studyinginfrequent but important clinical events

  35. chemobrain S6-3 NeurocognitiveImpact in AdjuvantChemotherapyforBreast Cancer LinkedtoFatigue: A ProspectiveFunctional MRI Study • Prospective non-randomizedcomparative trial n=28 n=37 n=32

  36. chemobrain S6-3 • Frontal Brain Activationbygroupand time

  37. chemobrain Resultsandconclusion S6-3 • Neurocognitivealterations in working memory processesandgreaterfatiguewere evident beforeanyadjuvantchemotherapy. • Pre-adjuvant treatment brainalterationsduringworking memory taskpredictseverity of fatiguepost-treatment. • Greaterfatigueacrossallgroups was relatedtoreducedcognitivefunctionover time.

  38. Bone S6-4 Vitamin D, But NotBone Turnover Markers, Predict Relapse In WomenWithEarlyBreastCancer: An AZURETranslationalStudy. And 25HO VitD

  39. Bone S6-4 Prognosticeffect onlyfor25HO VitD

  40. Bone S6-4 Predictiveeffect * 25HO Vit D * CTX, PINP : ZOL benefit NOT predictedbyhigherbone turnover

  41. Bone S3-13-01 LOTUS trial: Prospectivestudy of treatment pattern, effectiveness, andsafety of Zoledronic acid (ZOL) beyond 2y: subgroup analysis of ptswithmetastaticbreastcancer. • Population: 157 pts, 92% continued ZOL only37%receivedper label (q3-4w) • SRE: - SRE rate 0,13 per person yearduring 18 monthstudy (vs 0,13 in 18 monthsbeforeinclusion) - 83% SRE free at 18 months - persistent ZOL therapyper label ≈ lower SRE rate (HR 0,26 p 0,009) • Safety: - renaldeterioration in 6 pts - No symptomatichypoCa (but only 16% taking supplements!) - Acute phasereactions 9,5% - ONJ in 7 pts (4,5%)

  42. Bone Bisphosphonates • Neoadj FEC-paclitaxel +/- ZOL. PD07-05 • randomized trial (n= 182) • pCR 14,9 vs 7,9% (p 0,16) • in postmenopauzal 18,4 vs 5,4% (p 0,15) • iv ZOL vs po ibandronatPD09-07 • randomized trial (n=1405) • MBC withbone metastases • SRE rate per yearlowerfor ZOL (0,44 vs 0,54, p 0,02)

  43. Conclusions HER2 • HER2 adjuvant: • HERA and NSABP B-31/NCCTG N9831 results at 8 yrsFUP show sustained and statistically significant DFS and OS benefit for 1 year trastuzumabversus observation in ITT analyses despite selective crossover. No benefit for extension to 2 years in HERA. • PHARE failed to show that 6 months of trastuzumab is non inferior to 12 months. Subgroup analysis suggested that • Sequential modality for ER negative tumors impacted the overall results. • Results in other groups seemed compatible with non-inferiority hypothesis • 1 year of trastuzumab remains the standard of care as adjuvant therapy for patients with HER2-positive early breast cancer. • HER2 metastatic: • Addition of pertuzumabto trastuzumab and docetaxel improves OS and PFS significantly in HER2-positive first-line without important toxicity aspects.

  44. Conclusions supportive care • Adjuvantchemotherapyis associatedwith a cumulative10-year incidence of leukemiaof ~ 0.5% • Neurocognitivealterations in working memory processesandgreaterfatigueare present beforeanyadjuvantchemotherapy. • Low baseline VitD is associatedwithincreased risk of boneanddistantrecurrence

More Related